- Home
- GRND vs VCEL Comparison
GRND vs VCEL Comparison
Compare GRND & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | VCEL |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | GRND | VCEL |
|---|---|---|
| Price | $11.09 | $37.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $22.75 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 1.3M | 533.9K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $411,545,000.00 | $258,716,999.00 |
| Revenue This Year | $29.03 | $17.88 |
| Revenue Next Year | $21.87 | $18.58 |
| P/E Ratio | ★ N/A | $145.90 |
| Revenue Growth | ★ 28.97 | 14.05 |
| 52 Week Low | $11.11 | $29.24 |
| 52 Week High | $25.13 | $63.00 |
Technical Indicators
Market Signals| Indicator | GRND | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 16.03 | 48.36 |
| Support Level | $11.52 | $35.55 |
| Resistance Level | $12.01 | $37.20 |
| Average True Range (ATR) | 0.34 | 1.59 |
| MACD | -0.11 | -0.15 |
| Stochastic Oscillator | 0.00 | 36.13 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.